Merck KGaA (OTCMKTS:MKKGY - Get Free Report)'s share price rose 0.2% during mid-day trading on Wednesday . The stock traded as high as $26.33 and last traded at $26.22. Approximately 156,967 shares were traded during mid-day trading, an increase of 33% from the average daily volume of 118,303 shares. The stock had previously closed at $26.16.
Merck KGaA Price Performance
The company has a market cap of $17.27 billion, a price-to-earnings ratio of 12.66, a P/E/G ratio of 1.95 and a beta of 0.92. The company has a current ratio of 1.31, a quick ratio of 0.83 and a debt-to-equity ratio of 0.23. The business has a 50-day moving average price of $26.50 and a 200 day moving average price of $27.78.
Merck KGaA (OTCMKTS:MKKGY - Get Free Report) last released its quarterly earnings results on Thursday, May 15th. The company reported $0.59 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.50 by $0.09. The business had revenue of $5.89 billion for the quarter, compared to analyst estimates of $5.32 billion. Merck KGaA had a net margin of 13.23% and a return on equity of 9.61%. As a group, research analysts expect that Merck KGaA will post 1.87 earnings per share for the current fiscal year.
Merck KGaA Increases Dividend
The company also recently disclosed a dividend, which was paid on Wednesday, May 7th. Investors of record on Wednesday, April 30th were issued a $0.3382 dividend. The ex-dividend date was Tuesday, April 29th. This represents a yield of 1.25%. This is an increase from Merck KGaA's previous dividend of $0.32. Merck KGaA's dividend payout ratio is currently 15.64%.
About Merck KGaA
(
Get Free Report)
Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector.
See Also
Before you consider Merck KGaA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck KGaA wasn't on the list.
While Merck KGaA currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
